阿帕替尼一线治疗晚期肝癌疗效观察

柯少波; 汪晶; 邱虎; 蔡高科; 龚毅; 陈永顺

doi:10.3971/j.issn.1000-8578.2021.20.1161

阿帕替尼一线治疗晚期肝癌疗效观察

Therapeutic Effect of Apatinib in First-line Treatment of Advanced Liver Cancer

摘要

摘要:
目的探索阿帕替尼在晚期肝癌的一线治疗效应。
方法对2017年7月至2020年1月在武汉大学人民医院肿瘤中心治疗的晚期肝癌患者进行回顾性分析，纳入35例肝癌患者，所有患者均给予甲磺酸阿帕替尼片250~500 mg口服，每天1次。对于疾病控制有效的患者（包括CR、PR和SD）继续给药直至PD或无法耐受或死亡。主要终点为PFS和OS，次要终点为DCR、ORR，同时观察不良反应。
结果 CR 1例，PR 17例，SD 11例，ORR 51.43%，DCR 82.86%，中位PFS 9.7月，中位OS 11.1月。患者的主要不良反应有手足综合征、高血压、蛋白尿等，大多3~5级不良反应均可逆，安全性好。
结论阿帕替尼可以改善肝癌患者的临床获益、安全有效，是晚期肝癌可选择的一线方案。

Abstract:
Objective To explore the effect of apatinib in first-line treatment of advanced liver cancer.
Methods Retrospective analysis was performed on 35 patients with advanced liver cancer treated in our department from July 2017 to January 2020. All patients were given apatinib mesylate tablet 250-500 mg orally with QD. The patients with effective disease control (including CR, PR and SD) were given administration until PD or intolerance or death occurred. The primary endpoints were PFS and OS, and the secondary endpoints were DCR and ORR. The side effect was observed.
Results There was one case of CR, 17 cases of PR and 11 cases of SD. The ORR and DCR were 51.43% and 82.86%. The median PFS and OS were 9.7 and 11.1 months. The main adverse reactions included hand-foot syndrome, hypertension, proteinuria, etc. Most grade 3-5 adverse reactions were reversible with good safety.
Conclusion Apatinib can significantly improve the clinical benefits of liver cancer patients. It is an alternative first-line treatment for advanced liver cancer.

HTML全文

参考文献(19)

施引文献

资源附件(0)